Skip to main content

Table 2 Treatment decision and evaluation of descriptions

From: Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment

 

Delay of Events

Outcome

1 month

6 months

18 months

Overall

CHI-Square

P-value

Willingness to initiate treatment, % (n)

45.5 (156)

70.6 (243)

80.5 (268)

65.4 (667)

98.71a

< 0.001

Benefit from medication, md (q1, q3), m

3 (2,5), 3.18

4 (2,5), 3.99

5 (4,6), 4.58

4 (2,5), 3.91

96.20b

< 0.001

Feel safe with medication, md (q1, q3), m

3 (2,5), 3.45

4 (2,5), 3.95

4 (3,6), 4.25

4 (2,5), 3.88

30.35b

< 0.001

Be motivated to take medication, md (q1, q3), m

2 (1,5), 3.17

4 (2,6), 4.09

5 (3,6), 4.66

4 (2,6), 3.97

79.64b

< 0.001

Importance to adhere, md, (q1, q3), m

5 (2,7), 4.47

6 (4,7), 5.27

5 (5,7), 5.67

6 (4,7), 5.13

41.91b

< 0.001

Willingness to pay (Euro), md (q1, q3), mc

5 (0, 16), 13.4

10 (5, 30), 23.2

20 (10,30), 25.7

10 (0, 30), 20.8

65.10b

< 0.001

Use of information, md (q1, q3), m

5 (3,6), 4.63

5 (4,6), 4.65

5 (4,6), 4.91

5 (4,6), 4.72

3.25b

0.20

  1. aPearson Chi-Square
  2. bKruskal-Wallis H test
  3. cWillingness to pay was measured in Swedish krona (SEK) 1SEK/0.10 Euro (€)